Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Smith-Magenis syndrome chromosome region, candidate 5 (SMCR5), is a long non-coding RNA gene on chromosome 17 that does not encode a protein[3][5][9]. It is one of several genes found in the region commonly deleted in Smith-Magenis syndrome, a genetic disorder characterized by developmental delay and behavioral problems arising from deletions affecting multiple genes including RAI1, a gene with more direct pathogenic significance[11]. SMCR5 itself is not established as a therapeutic target, and while its specific biological functions are not well-characterized, lncRNAs are generally implicated in gene expression regulation, chromatin structure maintenance, and cell differentiation[2][6][8]. The existence of a SMCR5 protein product described in some sources is likely erroneous or at best unconfirmed, as major genomic databases list it solely as a non-protein coding RNA[3][5][7].
No established mechanism of action for drugs; general lncRNA mechanisms include gene expression modulation and chromatin interaction
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Smith-Magenis syndrome chromosome region, candidate 5 (non-protein coding) (SMCR5).